Euroscreen Appoints Jean Combalbert, Ph.D., as CEO

Euroscreen SA announced the appointment of Jean Combalbert, Ph.D. to the position of President & Chief Executive Officer. Dr. Combalbert joins Euroscreen with more than 15 years experience in pharmaceutical and biotech companies.

Brussels, Belgium (PRWEB) March 17, 2006 -- Euroscreen SA announced the appointment of Jean Combalbert, Ph.D. to the position of President & Chief Executive Officer. Dr. Combalbert joins Euroscreen with more than 15 years experience in pharmaceutical and biotech companies.

Dr. Combalbert received his PhD in Pharmacy from the University of Marseille, France. After his Ph.D. on pharmacokinetics and metabolism in French public research (INSERM), he joined the pharmaceutical industry where he had senior positions with Sanofi in Montpellier then with Galderma successively based in Sophia Antipolis, France, and then in Princeton, NJ, USA. Since 2003, he was Chairman & CEO of Entomed SA, of Strasbourg, France.

"Euroscreen is one of the top European biotechs positioned to meet its long-term objectives – in both drug discovery and in its products and services business activity," said Dr. Combalbert. "Using Euroscreen's GPCR science and technologies, we will continue to announce several major drug discovery partnerships this year, and enter into new license agreements for our high value patent portfolio, particularly for our combined CCR5 patent rights.”

About Euroscreen SA

Euroscreen is a biopharmaceutical company focusing on the discovery, development and partnering of small molecule drugs for unmet medical needs.

Euroscreen is developing a pipeline of compounds targeting G protein-coupled receptors (GPCRs) using over 11 years of experience in research and commercialization of this critical class of drug targets in association with the Institute of Interdisciplinary Research (IRIBHM) of the University of Brussels. The Company has developed a broad patent portfolio for licensing to biopharmaceutical companies. Such patents address targets such as CCR5, Chemerin receptor, GPR43, GPR7/8, purinergic receptors (P2Y4, P2Y11 and P2Y13) and SHIP2 for type II diabetes. Euroscreen’s AequoScreen™ cellular assay platform is used extensively in its screening of GPCRs for candidate drugs which are partnered during preclinical development.

Euroscreen’s strategy is combining its own drug discovery with its products and services business activity to serve biotech and pharmaceutical companies around the world. Euroscreen pursues internal drug targets as well as several partnered preclinical-stage collaborations with Cephalon, ChemDiv and MNLpharma. Euroscreen has research, product distribution and licensing partnerships with Amersham/GE Healthcare, Cephalon, ChemDiv, Evotec, ICOS, Merck & Co, MNLpharma, Pfizer Inc, Solvay, Syngenta and UCB.

Euroscreen is a privately held company based in Brussels, Belgium with 80 employees mainly involved in R&D.

###